Resultados de procura - Taebo Sim

Limitar resultados
  1. 1
    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8

    Development of Highly Potent and Selective Steroidal Inhibitors and Degraders of CDK8 por John M. Hatcher, Eric S. Wang, Liv Johannessen, Nicholas Kwiatkowski, Taebo Sim, Nathanael S. Gray

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1

    Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1 por Xianming Deng, Qingkai Yang, Nicholas Kwiatkowski, Taebo Sim, Ultan McDermott, Jeffrey Settleman, Jiing-Dwan Lee, Nathanael S. Gray

    Publicado 2011
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  3. 3
    A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout

    A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout por Kihyoun Park, Injae Shin, Y. Kim, Hyereen Kang, Soo Jin Oh, Eunkyeong Jang, Taebo Sim, Jeehee Youn, Myung Sik Lee

    Publicado 2024
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1

    An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-resistant Functions of mTORC1 por Carson C. Thoreen, Seong A. Kang, Jae Won Chang, Qingsong Liu, Jianming Zhang, Yi Gao, Laurie J. Reichling, Taebo Sim, David M. Sabatini, Nathanael S. Gray

    Publicado 2009
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer

    Identification of Existing Drugs That Effectively Target <i>NTRK1</i> and <i>ROS1</i> Rearrangements in Lung Cancer por Curtis R. Chong, Magda Bahcall, Marzia Capelletti, Takayuki Kosaka, Dalia Ercan, Taebo Sim, Lynette M. Sholl, Mizuki Nishino, Bruce E. Johnson, Nathanael S. Gray, Pasi A. Jänne

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1<i>H</i>)-one as a Highly Potent, Selective Mammalian Target of Rapamycin (mTOR) Inhibitor for the Treatment of Cancer

    Discovery of 1-(4-(4-Propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1<i>H</i>)-one as a Highly Potent, Selective Mammalian Target... por Qingsong Liu, Jae Won Chang, Jinhua Wang, Seong A. Kang, Carson C. Thoreen, Andrew L. Markhard, Wooyoung Hur, Jianming Zhang, Taebo Sim, David M. Sabatini, Nathanael S. Gray

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase

    Targeted kinase degradation via the KLHDC2 ubiquitin E3 ligase por Younghoon Kim, Pooreum Seo, Eunhye Jeon, Inchul You, Kyubin Hwang, Namkyoung Kim, Jason Tse, Ju‐Hyeon Bae, Ha‐Soon Choi, Stephen M. Hinshaw, Nathanael S. Gray, Taebo Sim

    Publicado 2023
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors

    A General Strategy for Creating “Inactive-Conformation” Abl Inhibitors por Okram Barun, A. S. Nagle, Francisco Adrián, Christian Lee, Pingda Ren, Xia Wang, Taebo Sim, Yongping Xie, Xing Wang, Gang Xia, Glen Spraggon, Markus Warmuth, Yi Liu, Nathanael S. Gray

    Publicado 2006
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Development of small molecules targeting the pseudokinase Her3

    Development of small molecules targeting the pseudokinase Her3 por Sang Min Lim, Ting Xie, Kenneth D. Westover, Scott B. Ficarro, Hyun Seop Tae, Deepak Gurbani, Taebo Sim, Jarrod A. Marto, Pasi A. Jänne, Craig M. Crews, Nathanael S. Gray

    Publicado 2015
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Expanding the Diversity of Allosteric Bcr-Abl Inhibitors

    Expanding the Diversity of Allosteric Bcr-Abl Inhibitors por Xianming Deng, Okram Barun, Qiang Ding, Jianming Zhang, Yongmun Choi, Francisco Adrián, Amy Wojciechowski, Guobao Zhang, Jianwei Che, Badry Bursulaya, Sandra W. Cowan‐Jacob, Gabriele Rummel, Taebo Sim, Nathanael S. Gray

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Covalent Guanosine Mimetic Inhibitors of G12C KRAS

    Covalent Guanosine Mimetic Inhibitors of G12C KRAS por Yuan Xiong, Jia Lu, John C. Hunter, Lianbo Li, David A. Scott, Hwan Geun Choi, Sang Min Lim, Anuj Manandhar, Sudershan Reddy Gondi, Taebo Sim, Kenneth D. Westover, Nathanael S. Gray

    Publicado 2016
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  12. 12
    Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function

    Small-molecule kinase inhibitors provide insight into Mps1 cell cycle function por Nicholas Kwiatkowski, Nannette Jelluma, P. Filippakopoulos, M. Soundararajan, Michael S. Manak, Mijung Kwon, Hwan Geun Choi, Taebo Sim, Quinn L. Deveraux, Sabine Rottmann, David Pellman, Jagesh V. Shah, Geert J.P.L. Kops, Stefan Knapp, Nathanael S. Gray

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Acquired <i>MET</i>D1228V Mutation and Resistance to MET Inhibition in Lung Cancer

    Acquired <i>MET</i>D1228V Mutation and Resistance to MET Inhibition in Lung Cancer por Magda Bahcall, Taebo Sim, Cloud P. Paweletz, Jyoti D. Patel, Ryan S. Alden, Yanan Kuang, Adrian G. Sacher, Nam Doo Kim, Christine Lydon, Mark M. Awad, Michael T. Jaklitsch, Lynette M. Sholl, Pasi A. Jänne, Geoffrey R. Oxnard

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl

    A Type-II Kinase Inhibitor Capable of Inhibiting the T315I “Gatekeeper” Mutant of Bcr-Abl por Hwan Geun Choi, Pingda Ren, Francisco Adrián, Fangxian Sun, Hyun Soo Lee, Xia Wang, Qiang Ding, Guobao Zhang, Yongping Xie, Jianming Zhang, Yi Liu, Tove Tuntland, Markus Warmuth, Paul W. Manley, Jürgen Mestan, Nathanael S. Gray, Taebo Sim

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones

    Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones por Xianming Deng, Jonathan M. Elkins, Jinwei Zhang, Qingkai Yang, Tatiana Erazo, Néstor Gómez, Hwan Geun Choi, Jinhua Wang, Nicolas Dzamko, Jiing-Dwan Lee, Taebo Sim, Namdoo Kim, Dario R. Alessi, José M. Lizcano, Stefan Knapp, Nathanael S. Gray

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Pharmacological targeting of the pseudokinase Her3

    Pharmacological targeting of the pseudokinase Her3 por Ting Xie, Sang Min Lim, Kenneth D. Westover, Michael Dodge, Dalia Ercan, Scott B. Ficarro, Durga Udayakumar, Deepak Gurbani, Hyun Seop Tae, Steven M. Riddle, Taebo Sim, Jarrod A. Marto, Pasi A. Jänne, Craig M. Crews, Nathanael S. Gray

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Inverse Agonist of Nuclear Receptor ERRγ Mediates Antidiabetic Effect Through Inhibition of Hepatic Gluconeogenesis

    Inverse Agonist of Nuclear Receptor ERRγ Mediates Antidiabetic Effect Through Inhibition of Hepatic Gluconeogenesis por Don‐Kyu Kim, Gil-Tae Gang, Dongryeol Ryu, Minseob Koh, Yo-Na Kim, Su Sung Kim, Jinyoung Park, Yong‐Hoon Kim, Taebo Sim, In‐Kyu Lee, Cheol Soo Choi, Seung Bum Park, Chul‐Ho Lee, Seung‐Hoi Koo, Hueng-Sik Choi

    Publicado 2013
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2)

    Discovery of Type II Inhibitors of TGFβ-Activated Kinase 1 (TAK1) and Mitogen-Activated Protein Kinase Kinase Kinase Kinase 2 (MAP4K2) por Li Tan, Tyzoon Nomanbhoy, Deepak Gurbani, Matthew P. Patricelli, John C. Hunter, Jiefei Geng, Lina Herhaus, Jianming Zhang, Eduardo Pauls, Youngjin Ham, Hwan Geun Choi, Ting Xie, Xianming Deng, Sara J. Buhrlage, Taebo Sim, Philip Cohen, Gopal P. Sapkota, Kenneth D. Westover, Nathanael S. Gray

    Publicado 2014
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor

    Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor por Sang Min Lim, Kenneth D. Westover, Scott B. Ficarro, Rane A. Harrison, Hwan Geun Choi, Michael E. Pacold, Martin A. Carrasco, John C. Hunter, Nam Doo Kim, Ting Xie, Taebo Sim, Pasi A. Jänne, Matthew Meyerson, Jarrod A. Marto, John R. Engen, Nathanael S. Gray

    Publicado 2013
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

    Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome por Suman Rao, Deepak Gurbani, Guangyan Du, Robert A. Everley, Christopher M. Browne, A. Chaikuad, Li Tan, Martin Schröder, Sudershan Reddy Gondi, Scott B. Ficarro, Taebo Sim, Nam Doo Kim, Matthew J. Berberich, Stefan Knapp, Jarrod A. Marto, Kenneth D. Westover, Peter K. Sorger, Nathanael S. Gray

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: